Rituximab or rituximab hyaluronidase human    (DrugBank: Rituximab, Hyaluronidase)

1 disease
IDDisease name (Link within this page)Number of trials
331Idiopathic multicentric castleman disease1

331. Idiopathic multicentric castleman disease    [ 30 clinical trials,   44 drugs,   (DrugBank: 23 drugs),   30 drug target genes,   148 drug target pathways]
Searched query = "Idiopathic multicentric castleman disease", "Castleman disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 30 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03864419
(ClinicalTrials.gov)
October 24, 20191/3/2019Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in UgandaA Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castleman Disease in Pediatrics and Adults in UgandaBurkitt Lymphoma;KSHV-associated Multicentric Castleman Disease;Diffuse Large B-Cell LymphomaBiological: Rituximab or Rituximab Hyaluronidase Human;Drug: Cyclophosphamide;Drug: Vincristine;Drug: Methotrexate;Drug: Doxorubicin;Drug: Doxorubicin Hydrochloride;Drug: Prednisone;Drug: EtoposideFred Hutchinson Cancer Research CenterNational Cancer Institute (NCI)Recruiting2 YearsN/AAll40Phase 1Uganda;United States